Please provide your email address to receive an email when new articles are posted on . Pharmaceutical executives fielded questions on the costs of insulin and other prescription drugs during a recent ...

About 3 times as many of the children and teenagers taking dulaglutide had a glycated hemoglobin level of less than 7.0% at 26 weeks compared with those on placebo. Treatment with a once-weekly dose ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. (HealthDay News) — For patients with inadequately controlled type 2 diabetes ...

VIENNA — Tirzepatide (Mounjaro) is cardioprotective in people with type 2 diabetes (T2D) and established atherosclerotic cardiovascular (CV) disease, but not more so than dulaglutide (Trulicity), ...

Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...